Pneumocystis carinii is a frequent cause of infection in immunocompromised individuals. Between 60 and 80% of all patients with AIDS suffer one or more episodes of pneumonia caused by P. carinii. Although prophylaxis with the combination of trimethoprim and sulfamethoxazole is effective in preventing pneumonia in children being treated for acute lymphocytic leukemia or in those with congenital immune deficiencies (10) , severe adverse reactions preclude its use for prophylaxis in many patients with AIDS (12) . Likewise, as therapeutic agents, both pentamidine and trimethoprim-sulfamethoxazole cause adverse reactions. Additional drugs are needed both for prophylaxis and for therapy of P. carinii pneumonia, particularly for those patients with AIDS. Both antiparasitic and antifungal drugs have been proposed as potential therapeutic agents. Although most antifungal agents have not proven useful (4) and some antiparasitic agents have been shown to have activity (19) , most drug regimens have incorporated compounds which act as anti-folate pathway agents. Drugs which act against P. carinii by new and unique mechanisms could greatly enhance our ability to treat or prevent P. carinii pneumonia.
Benzimidazole derivatives are known to act against microtubules in other organisms, and it was hypothesized that they might show activity against the microtubules of P. carinii. Microtubules are important components of all eukaryotic cells. They form the mitotic spindle for chromosome segregation. In many cells, they function in motility by forming cilia and flagella, and they also serve as major cytoskeletal elements. Microtubules are formed by the polymerization of cx-and 1-tubulin protein subunits. Several drug groups inhibit microtubule polymerization; however, the benzimidazoles are the most important of these in terms of their clinical applications (15) . At least 10 currently marketed benzimidazole derivatives have high inhibitory activities against helminths but low toxicities for mammalian cells. The related benzimidazoles benomyl and carbendazim are highly active antifungal agents used in agriculture. Recently, it has been reported that some protozoa (Trichomonas vaginalis and Giardia lamblia) also are highly suscepti-ble to benzimidazoles, specifically the anthelminthic derivatives (9, 13) . Results of the studies with a group of benzimidazoles that are active against fungi, helminths, and protozoa reported here demonstrate that they have potentially useful activity against P. carinii as well.
MATERIALS AND METHODS
Ten benzimidazole derivatives were tested by using an in vitro system described previously (1) . Briefly, drugs dissolved in dimethyl sulfoxide were diluted to concentrations of 10, 1.0, and 0.1 pLg/ml in minimum essential medium used for the culture of human embryonic lung fibroblasts. The final maximum dimethyl sulfoxide concentration was 0.1%, a concentration of dimethyl sulfoxide that did not affect P. carinii proliferation when it was used alone and that gave P. carinii growth curves comparable to those of organisms in untreated control wells. Cell cultures in 24-well plates were inoculated with P. carinii trophozoites (final concentration, about 7 x 105 per ml) obtained from infected rat lungs (2) . Each culture plate contained untreated and trimethoprimsulfamethoxazole-treated (50/250 ,ug/ml) wells, in addition to the benzimidazole-treated wells. Plates were incubated at 35°C in a gas mixture of 5% 02-10% C02-85% N2 for up to 7 days. Plates were sampled on days 1, 3, 5, and 7 by removal of 10-pI amounts after agitation of the cultures. The samples were placed on slides in 1-cm2 areas, fixed in methanol, and stained with Giemsa stain; and then they were examined microscopically as unknowns by two individuals. For each parameter there were four wells, making eight values for each parameter. Means and standard errors were used to construct growth curves.
RESULTS
All nine anthelminthic and antifungal benzimidazole derivatives tested were inhibitory to P. carinii at 10 ,ug/ml. In comparison, the parent compound, benzimidazole, had no effect at that concentration (Fig. 1A ). The only derivative tested that was effective at 10 but not at 1.0 ,ug/ml was thiabendazole (Fig. 1A) . All other antimicrotubule drugs tested were effective at 1.0 ,ug/ml (Fig. 1B) . Only one of the drugs tested, parbendazole, was effective at 0.1 ig/ml (Fig.  1C) . The variation in effectiveness of the benzimidazole derivatives tested led us to examine the structures for chemical correlates of effectiveness (Table 1 ). The two compounds with substituents other than NHCOOCH3 (carbamate) at R2 (i.e., benzimidazole and thiabendazole) were more than 10-fold less effective than all other derivatives tested.
Among the remaining compounds, differences in potency were associated with the nature of the substituent on carbon 5, with a simple aliphatic substituent (i.e., parbendazole) being favored over sulfur-and oxygen-containing aliphatic substituents (albendazole, oxibendazole), aromatic substituents (fenbendazole, oxfendazole, mebendazole), or a simple hydrogen substituent (carbendazim).
DISCUSSION
The short-term culture method used here has predicted the efficacies of a variety of compounds for the treatment of P. cannii in animal models and in humans. These compounds 
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BARTLETT ET AL. With information on the activities of these compounds in vitro, those that appear to be the most promising may be selected for use in trials in animal models. In addition, structural changes may be evaluated for their influence on the activities of the compounds in the culture method before progressing to evaluation in animals.
The effectiveness of parbendazole at the low concentration of 0.1 ,ug/ml should prompt early studies of this compound in animals. Finally, the discovery of compounds with activities against microtubules in other organisms provides a strong impetus for pursuing molecular studies of microtubules in P. cannii. Those studies are under way (8) .
